EMA Authorised: Amgevita (adalimumab) — Amgen Europe B.V.

View source ↗

Summary

EMA has authorised Amgevita (adalimumab) by Amgen Europe B.V., a biosimilar of adalimumab, for multiple inflammatory diseases including rheumatoid arthritis, ps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Juvenile Idiopathic Arthritis
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• Amgevita (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Colitis, Ulcerative;Arthritis, Juvenile Rheumatoid;Spondylitis, Ankylosing;Psoriasis;Crohn Disease;Arthritis, Rheumatoid. MAH: Amgen Europe B.V.. Decision date: 23/04/2026